Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 3350; macrogol 400 - apo-mupirocin is indicated for the topical treatment of mild impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.